{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:55:19Z","timestamp":1777294519856,"version":"3.51.4"},"reference-count":23,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T00:00:00Z","timestamp":1486771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The purpose of this study was to examine the prognostic capability of baseline neutrophil-to-lymphocyte-ratio (NLR) and NLR-change under Abiraterone in metastatic castration-resistant prostate cancer patients. The impact of baseline NLR and change after eight weeks of treatment on progression-free survival (PFS) and overall survival (OS) was analyzed using Kaplan-Meier-estimates and Cox-regression. 79 men with baseline NLR &lt;5 and 17 with NLR &gt;5 were analyzed. In baseline analysis of PFS NLR &gt;5 was associated with non-significantly shorter median PFS (five versus 10 months) (HR: 1.6 (95%CI:0.9\u20132.8); p = 0.11). After multivariate adjustment (MVA), ECOG &gt; 0\u20131, baseline LDH&gt;upper limit of normal (UNL) and presence of visceral metastases were independent prognosticators. For OS, NLR &gt;5 was associated with shorter survival (seven versus 19 months) (HR: 2.3 (95%CI:1.3\u20134.0); p &lt; 0.01). In MVA, ECOG &gt; 0\u20131 and baseline LDH &gt; UNL remained independent prognosticators. After 8 weeks of Abiraterone NLR-change to &lt;5 prognosticated worse PFS (five versus 12 months) (HR: 4.1 (95%CI:1.1\u201315.8); p = 0.04). MVA showed a trend towards worse PFS for NLR-change to &lt;5 (p = 0.11). NLR-change to &lt;5 led to non-significant shorter median OS (seven versus 16 months) (HR: 2.3 (95%CI:0.7\u20137.1); p = 0.15). MVA showed non-significant difference for OS. We concluded baseline NLR &lt;5 is associated with improved survival. In contrast, in patients with baseline NLR &gt;5, NLR-change to &lt;5 after eight weeks of Abiraterone was associated with worse survival and should be interpreted carefully.<\/jats:p>","DOI":"10.3390\/ijms18020380","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T10:09:07Z","timestamp":1487153347000},"page":"380","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2569-4446","authenticated-orcid":false,"given":"Martin","family":"Boegemann","sequence":"first","affiliation":[{"name":"Department of Urology, Prostate Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Schlack","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6767-1085","authenticated-orcid":false,"given":"Stefan","family":"Thomes","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Steinestel","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kambiz","family":"Rahbar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Muenster University Medical Center, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Semjonow","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Schrader","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dresden University Medical Center, Fetscherstra\u00dfe 74, D-01307 Dresden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura-Maria","family":"Krabbe","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, Germany"},{"name":"Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"Oudard","year":"2010","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"\u03b1 emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-11-0815","article-title":"Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response","volume":"17","author":"Ryan","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/annonc\/mdu587","article-title":"Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use","volume":"26","author":"Lorente","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Luo, Y., She, D.L., Xiong, H., Fu, S.J., and Yang, L. (2015). Pretreatment Neutrophil to Lymphocyte Ratio as a Prognostic Predictor of Urologic Tumors: A Systematic Review and Meta-Analysis. Medicine, 94.","DOI":"10.1097\/MD.0000000000001670"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijsu.2015.07.681","article-title":"The prognostic role of neutrophils to lymphocytes ratio and platelet count in gastric cancer: A meta-analysis","volume":"21","author":"Dong","year":"2015","journal-title":"Int. J. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1245\/s10434-015-4869-5","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: A systematic review and meta-analysis","volume":"23","author":"Yodying","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1634\/theoncologist.2012-0125","article-title":"Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: Association with outcome and predictive nomogram","volume":"17","author":"Keizman","year":"2012","journal-title":"Oncologist"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.clgc.2014.03.005","article-title":"Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer","volume":"12","author":"Sonpavde","year":"2014","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdu569","article-title":"Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: Data from two randomized phase III trials","volume":"26","author":"Templeton","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdt581","article-title":"Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer","volume":"25","author":"Templeton","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.semcancer.2013.02.001","article-title":"Immunomonitoring and prognostic relevance of neutrophils in clinical trials","volume":"23","author":"Donskov","year":"2013","journal-title":"Semin. Cancer Biol"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","article-title":"The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer","volume":"88","author":"Guthrie","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1161\/01.CIR.98.21.2307","article-title":"Glucocorticoid-induced granulocytosis: Contribution of marrow release and demargination of intravascular granulocytes","volume":"98","author":"Nakagawa","year":"1998","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fphar.2016.00123","article-title":"Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival","volume":"7","author":"Facchini","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/2\/380\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:28:03Z","timestamp":1760207283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/2\/380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,11]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2]]}},"alternative-id":["ijms18020380"],"URL":"https:\/\/doi.org\/10.3390\/ijms18020380","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,11]]}}}